Mazzotti reactions | After OCP-patch | After LTS-2 patch |
---|---|---|
Itching at patch application site: n (%)* | 19 (63.3Â %) at OCP-patch site | 6 (20.0Â %) at LTS-2 patch site |
 |  | 3 (10.0 %) at OCP-patch siteb |
 Start (hrs after patch application)a Mean ± SD | 12.6 ± 13.4 | 6.9 ± 6.9 at LTS-2 patch site |
 Start (hrs after patch application)a Range (Median) | 0.8–52.0 (8.2) | 1.5–19.4 (4.1) at LTS-2 patch site |
 |  | 0.1, 0.5, 4.1 + 36.1 – at OCP-patch |
 Duration (hrs): Mean ± SDa, ** | 8.9 ± 11.8 | 1.0 ± 2.5 at LTS2 patch |
 Duration (hrs): Range (Median) | 0–56 (7.63) | 0–8.9 (0) – at LTS–2 patch |
 Duration (hrs) |  | 1.1, 4, 6 + 12 – at OCP-patch |
Itching involving the whole body: n (%) | 5 (16.7) | 2 (6.7Â %) |
 Start (hrs after patch application) | 4.1, 28.1, 51.9, 36.4, 4.3 | 5.7, 13.2 |
 Duration (hrs) | 7.9, 8.0, 8.2, 23.8, 55.9 | 6.3, 15.0 |
Itching at back | 1 (3.3Â %) | 0 |
Other clinical Mazzotti reactions | Â | Â |
 Burning sensation at patch sitec | 2 (6.7 %) | 0 |
 Pain at patch site | 1 (3.3 %) | 0 |
Haematological/biochemical reactions | Â | Â |
 Leucocytosis with increase in peripheral granulocytes | 4 (13.3) | 6 (20.0 %) |
 Increase in AST | 3 (10 %)d | 0 |
 Increase in ALT | 3 (10 %)d | 4 (13.3 %) + 2 (6.7 %d) |
 Increase in ALP | 0 | 2 (6.7 %) |